Synaptic dysfunction is recognized as one of the earliest and most critical events in neurodegenerative diseases. The intricate organization of synapses, with their complex molecular machinery, becomes progressively disrupted in conditions such as Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease. Understanding synaptic organization provides crucial insights into disease mechanisms and identifies potential therapeutic targets.
Synaptic organization refers to the structural and functional arrangement of synapses, the specialized junctions between [neurons](/entities/neurons) that enable neurotransmission. In neurodegenerative diseases, synaptic dysfunction is an early and critical event that precedes neuronal death. The loss of synaptic proteins, altered synaptic morphology, and impaired synaptic plasticity contribute to cognitive decline and motor deficits in conditions like Alzheimer disease, Parkinson disease, and Huntington disease. [@bellenchi2021]
Synaptic dysfunction is recognized as one of the earliest and most critical events in neurodegenerative diseases. The intricate organization of synapses, with their complex molecular machinery, becomes progressively disrupted in conditions such as Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease. Understanding synaptic organization provides crucial insights into disease mechanisms and identifies potential therapeutic targets.
Synaptic organization refers to the structural and functional arrangement of synapses, the specialized junctions between [neurons](/entities/neurons) that enable neurotransmission. In neurodegenerative diseases, synaptic dysfunction is an early and critical event that precedes neuronal death. The loss of synaptic proteins, altered synaptic morphology, and impaired synaptic plasticity contribute to cognitive decline and motor deficits in conditions like Alzheimer disease, Parkinson disease, and Huntington disease. [@bellenchi2021]
Synapses consist of presynaptic terminals containing neurotransmitter vesicles, a synaptic cleft, and postsynaptic densities with neurotransmitter receptors. Proper synaptic organization requires precise protein targeting, cytoskeletal support, and activity-dependent remodeling. Disruption of any component can lead to synaptic failure. [@lepeta2022]
The presynaptic terminal is specialized for neurotransmitter release: [@sheng2019]
The postsynaptic density (PSD) is a specialized structure beneath the postsynaptic membrane: [@harris2021]
The synaptic cleft (20-30 nm) contains:
Presynaptic Changes:
Dopaminergic Synapses:
Cortical Synapses:
Striatal Synapses:
The active zone is the specialized region of the presynaptic terminal where synaptic vesicles undergo docking, priming, and Ca²⁺-triggered fusion. Active zone dysfunction is increasingly recognized as a critical early event in neurodegenerative diseases. [@tauris2022]
The active zone scaffold comprises multiple protein families:
RIM Proteins (Rab3-interacting molecules): RIM1 and RIM2 organize the active zone and regulate vesicle priming. In AD models, RIM1α levels are reduced, impairing the readily releasable pool of synaptic vesicles.
Munc13 Proteins: These priming factors convert docked vesicles into fusion-competent vesicles. Munc13-1 deficiency leads to severe synaptic transmission deficits.
Piccolo and Bassoon: These large scaffold proteins tether synaptic vesicles to the active zone cytomatrix. Their dysfunction contributes to impaired vesicle replenishment.
Alzheimer's Disease: Active zone proteins including RIM1, Munc13, and Bassoon show reduced expression in early AD. This contributes to impaired synaptic vesicle replenishment and reduced synaptic strength.
Parkinson's Disease: Dopaminergic terminals show specific deficits in active zone organization. The high-frequency firing pattern of dopaminergic neurons demands efficient active zone function.
ALS: Corticomotor synapses show hyperactivity at the active zone, with dysregulated release kinetics contributing to excitotoxicity.
The postsynaptic density (PSD) is a specialized protein lattice beneath the postsynaptic membrane that anchors receptors and organizes signaling. [@heck2023]
The PSD contains over 1,000 proteins organized into functional modules:
Scaffold Proteins: PSD-95 (DLG4), PSD-93, SAP97, and Shank proteins form the structural backbone. These proteins link receptors to downstream signaling pathways and the actin cytoskeleton.
Receptor Complexes: NMDA receptors, AMPA receptors, GABA receptors, and metabotropic glutamate receptors are anchored through interactions with scaffold proteins.
Signaling Molecules: kinases, phosphatases, and second messenger enzymes are localized to the PSD for activity-dependent modulation.
AD: PSD-95 levels are reduced early in disease, correlating with cognitive decline. Tau pathology disrupts PSD organization through mislocalization of PSD proteins.
PD: Dopamine receptor signaling is altered through PSD dysfunction. D1 and D2 receptor anchoring to scaffolds is impaired.
Synaptic adhesion molecules mediate trans-synaptic signaling and maintain synaptic stability. [@volpato2023]
Neurexin-Neuroligin: These trans-synaptic adhesion pairs regulate synapse formation and function. Neurexin binding to neuroligins triggers postsynaptic assembly.
Leucine-rich repeat transmembrane proteins (LRRTMs): Alternative synaptogenic adhesion molecules that induce excitatory synapse formation.
Synaptic cell adhesion molecules (SynCAMs): Immunoglobulin superfamily members that mediate adhesive interactions across the synaptic cleft.
In AD, neurexin and neuroligin expression is altered, contributing to synaptic loss. In PD, synaptic adhesion molecule function is impaired by alpha-synuclein pathology.
Synaptic terminals contain specialized mitochondria that support the high energy demands of synaptic vesicle cycling and calcium buffering. [@choi2024]
Energy Production: Synaptic mitochondria generate ATP to power vesicle proton pumps, calcium pumps, and cytoskeletal motors.
Calcium Handling: Synaptic mitochondria buffer calcium during high-frequency activity, preventing calcium overload.
Reactive Oxygen Species: Mitochondrial respiration generates ROS that can damage synaptic components.
AD: Synaptic mitochondria show reduced efficiency and increased ROS production. Aβ accumulates in synaptic mitochondria, impairing function.
PD: Alpha-synuclein binds to synaptic mitochondria, impairing function. Mitochondrial dysfunction contributes to dopaminergic terminal vulnerability.
ALS: Motor nerve terminals show severe mitochondrial dysfunction, contributing to energy deficits.
Microglia and astrocytes mediate neuroinflammation that directly affects synaptic function. [@liu2023]
Complement-Mediated Pruning: Microglia use complement proteins C1q and C3 to tag synapses for elimination. Excessive complement activation leads to pathological synapse loss.
TREM2 Signaling: TREM2 on microglia regulates synapse phagocytosis. TREM2 variants increase AD risk through enhanced synaptic elimination.
Astrocytes provide metabolic and trophic support to synapses. Astrocyte dysfunction contributes to synaptic decline in neurodegeneration.
Synaptic plasticity—the activity-dependent modification of synaptic strength—is impaired in neurodegenerative diseases. [@patel2023]
LTP, the cellular basis for learning and memory, is impaired in AD through multiple mechanisms:
LTD is enhanced in AD, contributing to memory deficits. Enhanced LTD involves overactivation of NMDA receptors and excess calcium influx.
Homeostatic mechanisms that maintain stable network function are impaired in neurodegeneration. Synaptic scaling and multiplicative changes are dysregulated.
CSF biomarkers reflecting synaptic integrity are emerging as diagnostic and monitoring tools. [@johnson2024]
SNAP-25: Reduced CSF SNAP-25 correlates with cognitive decline in AD.
Synaptotagmin-1: Elevated CSF synaptotagmin may reflect synaptic degeneration.
Neurogranin: Postsynaptic protein that correlates with synaptic loss in AD.
Synaptic biomarkers may help identify patients early, monitor disease progression, and assess treatment response.
Ionotropic glutamate receptors are the primary mediators of excitatory synaptic transmission: [@kim2024]
NMDA Receptors: Require both glutamate and membrane depolarization for activation. NMDARs are permeable to Ca²⁺, making them critical for synaptic plasticity. In AD, NMDAR function is altered through multiple mechanisms including tau pathology and Aβ interaction.
AMPA Receptors: Mediate fast excitatory transmission. AMPAR trafficking is activity-dependent and underlies changes in synaptic strength. In AD, AMPAR trafficking is impaired, contributing to LTP deficits.
Kainate Receptors: Less understood but implicated in synaptic plasticity and disease.
AMPA receptor trafficking abnormalities are a hallmark of synaptic dysfunction in AD:
GABAergic inhibitory synapses are also affected in neurodegeneration: [@chen2023]
Disruption of inhibitory signaling contributes to:
Dendritic spines are the primary sites of excitatory synapses:
Spine Morphology: Spine shape correlates with synaptic strength. Mushroom spines are stable and mature, while thin spines are plastic. In AD, spine density decreases and morphological abnormalities appear.
Spine Dysfunction: Tau pathology affects spine integrity through both pre- and postsynaptic mechanisms. Aβ oligomers reduce spine density.
Presynaptic boutons show disease-specific changes:
The number of synapses relative to neuronal cell bodies is a critical metric:
AD: Synapse loss exceeds neuronal loss in early stages. Synapse-to-neuron ratio decreases dramatically.
PD: Specific loss of dopaminergic synapses in striatum.
ALS: Neuromuscular junction synapses are early targets.
AMPAkines: Positive allosteric modulators of AMPA receptors that enhance synaptic transmission. Under investigation for AD.
Nicotinic Agonists: Nicotinic acetylcholine receptors support synaptic function. Nicotine and analogs have been studied in AD.
mGluR Modulators: Metabotropic glutamate receptor modulators can enhance or suppress synaptic plasticity.
Neurotrophic Factors: BDNF and related molecules support synaptic maintenance and plasticity. Gene therapy approaches are in development.
Synaptic Scaffold Stabilizers: Compounds that stabilize PSD-95 and other scaffold proteins.
Cell Adhesion Enhancers: Approaches to strengthen neurexin-neuroligin interactions.
Environmental Enrichment: Sensory and cognitive stimulation promotes synaptic formation.
Physical Activity: Exercise enhances synaptic plasticity through multiple mechanisms.
Cognitive Training: Targeted cognitive exercises may preserve synaptic function.